Comparison of imidazole- and 2-methyl imidazole-containing farnesyl- protein transferase inhibitors: Interaction with and metabolism by rat hepatic cytochrome P450s

Drug Metabolism and Disposition

Volumn 28, Issue 6, 2000, Pages 680-686

  Tang, Cuyue ^a   Chiba, Masato ^a   Nishime, Joy ^a   Hochman, Jerome H ^a   Chen, I Wu ^a   Williams, Theresa M ^a   Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 [2 BUTYL 5 OXO 4 (5,6,7,8 TETRAHYDRO 1 NAPHTHYL) 1 PIPERAZINYLMETHYL] 1 IMIDAZOLYLMETHYL]BENZONITRILE; 4 [5 [4 (3 TRIFLUOROMETHOXYPHENYL) 3 OXOPIPERAZIN 6 BUTYL 1 YLMETHYL] 2 METHYL IMIDAZOL 1 YLMETHYL]BENZONITRILE; 4 [5 [4 (3 TRIFLUOROMETHOXYPHENYL) 3 OXOPIPERAZIN 6 BUTYL 1 YLMETHYL]IMIDAZOL 1 YLMETHYL]BENZONITRILE; 4 [5 [4 (5,6,7,8 TETRAHYDRONAPHTHALENYL) 3 OXOPIPERZIN 6 BUTYL 1 YLMETHYL]IMIDAZOLE 1 YLMETHYL]BENZONITRILE; BENZONITRILE; CYTOCHROME P450; CYTOCHROME P450 3A; IMIDAZOLE DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; ENZYME ACTIVITY; LIVER MICROSOME; MALE; METHYLATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0034129834     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-9556(24)15148-3     Document Type: Article

References (34)

1. Ahmed S, Smith JH, Nicholls PJ, Whomsley R and Cariuk P (1995) Synthesis and biological evaluation of imidazole based compounds as cytochrome P-450 inhibitors. Drug Des Discov 13:27-41.
2. Anthony NJ, Gomez RP, Schaber MD, Mosser SD, Hamilton KA, O'Neil TJ, Koblan KS, Graham SL, Hartman GD, Shah D, Rands E, Kohl NE, Gibbs JB and Oliff AI (1999) Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase. J Med Chem 42:3356-3368.
3. Casey PJ, Solski PA, Der CJ and Buss JE (1989) p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 86:8323-8327.
4. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E and Sauter T (1998) Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 28:1-13.
5. Dinsmore CJ, Williams TM, O'Neill TJ, Liu D, Rands E, Culberson JC, Lobell RB, Koblan KS, Kohl NE, Gibbs JB, Oliff AI, Graham SL and Hartman GD (1999) Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase. Bioorg Med Chem Lett 9:3301-3306.
6. Fujila S, Chiba M, Ohta M, Kitani K and Suzuki T (1990) Alteration of plasma sex hormone levels associated with old age and its effect on hepatic drug metabolism in rats. J Pharmacol Exp Ther 253:369-374.
7. Gibbs JB (1991) Ras C-terminal processing enzymes-new drug targets? Cell 65:1-4.
8. Gibbs JB, Oliff A and Kohl NE (1994) Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175-178.
9. Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, Scolnick EM, Kohl NE and Oliff A (1993) Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo. J Biol Chem 268:7617-7620.
10. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanisms and Biochemistry (Ortiz de Montellano PR ed) pp 473-575, Plenum Press, New York.
11. Halpert JR (1995) Structural basis of selective cytochrome P450 inhibition. Annu Rev Pharmacol Toxicol 35:29-53.
12. Hooper WD (1999) Metabolic drug interactions, in Handbook of Drug Metabolism (Woolf TF ed) pp 229-238, Marcel Dekker, New York.
13. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
14. Houston JB and Carlile DJ (1997) Incorporation of in vitro drug metabolism data into physiologically-based pharmacokinetic models. Toxicology in Vitro 11:473-478.
15. Hunt JT, Lee VG, Leftheris K, Seizinger B, Carboni J, Mabus J, Ricca C, Yan N and Manne V (1996) Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. J Med Chem 39:353-358.
16. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE and Der CJ (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89:6403-6407.
17. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A and Gibbs JB (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (Wash DC) 260:1934-1937.
18. Leonard DM, Shuler KR, Poulter CJ, Eaton SR, Sawyer TK, Hodges JC, Su TZ, Scholten JD, Gowan RC, Sebolt Leopold JS and Doherty AM (1997) Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J Med Chem 40:192-200.
19. Li AP, Kaminski DL and Rasmussen A (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8.
20. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
21. Miranda CL, Henderson MC and Buhler DR (1998) Evaluation of chemicals as inhibitors of trout cytochrome P450s. Toxicol Appl Pharmacol 148:237-244.
22. Moores SL, Schaber MD, Mosser SD, Rands E, O'Hara MB, Garsky VM, Marshall MS, Pompliano DL and Gibbs JB (1991) Sequence dependence of protein isoprenylation. J Biol Chem 266:14603-14610.
23. Orishiki M, Matsuo Y, Nishioka M and Ichikawa Y (1994) In vivo administration of H2 blockers, cimetidine and ranitidine, reduced the contents of the cytochrome P450IID (CYP2D) subfamily and their activities in rat liver microsomes. Int J Biochem 26:751-758.
24. Ortiz de Montellano PR and Correia MA (1995) Inhibition of cytochrome P-450 enzymes, in Cytochrome P-450: Structure, Mechanism and Biochemistry (Ortiz de Montellano PR ed) pp 305-364, Plenum Press, New York.
25. Reiss Y, Goldstein JL, Seabra MC, Casey PJ and Brown MS (1990) Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 62:81-88.
26. Rodenhuis S (1992) Ras and human tumors. Semin Cancer Biol 3:241-247.
27. Rogerson TD, Wilkinson CF and Hetarski K (1977) Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes. Biochem Pharmacol 26:1039-1042.
28. Ryan DE and Levin W (1990) Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther 45:153-239.
29. Schaefer W (1997) 2nd Annual Northeast/Mid Atlantic Finnigan Users' Meeting, November 11, 1997, Berks County, PA.
30. Schenkman JB, Sugar SG and Cinti DL (1982) Substrate interaction with cytochrome P-450, in Hepatic Cytochrome P-450 Monooxygease System (Schenkman JB and Kupfer D eds) pp 587-615, Pergamon, New York.
31. Waxman DJ (1984) Rat hepatic cytochrome P-450 isoenzyme 2c. Identification as a male-specific, developmentally induced steroid 16 alpha-hydroxylase and comparison to a female-specific cytochrome P-450 isoenzyme. J Biol Chem 259:15481-15490.
32. Waxman DJ, Dannan GA and Guengerich FP (1985) Regulation of rat hepatic cytochrome P-450: Age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry 24:4409-4417.
33. Wilkinson CF, Hetnarski K, Cantwell GP and Di Carlo FJ (1974) Structure-activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation in vitro and in vivo. Biochem Pharmacol 23:2377-2386.
34. Williams TM, Bergman JM, Brashear K, Breslin MJ, Dinsmore CJ, Hutchinson JH, MacTough SC, Stump CA, Wei DD, Zartman CB, Bogusky MJ, Culberson JC, Buser-Doepner C, Davide J, Greenberg IB, Hamilton KA, Koblan KS, Kohl NE, Liu D, Lobell RB, Mosser SD, O'Neill TJ, Rands E, Schaber MD and Huff JR (1999) N-arylpiperazinone inhibitors of farnesyltransferase: Discovery and biological activity. J Med Chem 42:3779-3784.